Date: 2011-04-01
Type of information: Private placement
Company: Neovacs (France)
Investors: Debioinnovation (Switzerland) - OTC Asset Management (France) - Truffle Capital (France)
Amount: € 2.25 million
Funding type: private placement
Planned used:
Others: Neovacs has announced a capital increase of € 2.25 million, via the issuance of shares at 4€ per share. Debioinnovation SA, subsidiary of the Swiss Debiopharm Group, subscribed for € 1 million; Truffle Capital, the lead institutional investor in the Company and OTC Asset Management also subscribed to the capital increase in the amount of € 1.25 million, also at €4 per share. Neovacs issued 562,500 new shares for this capital increase. The number of shares has been raised from 12,991,676 to 13,554,173.
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
